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ABSTRACT: Ocimum basilicum L. (Sweet Basil) is a medicinal herb used in traditional Indian and Chinese 
medicine to treat a variety of disease conditions including hypertension, and has well established 
antihypertensive effects among renovascular hypertensive rats. The aim of this study was to evaluate the 
antihypertensive effects of O. basilicum as adjunct in the management of stage 1 and 2 hypertensive patients. 
A double blind-randomized controlled trial was performed, with participants (n=24) randomized into a control 
and treatment group. Participants randomized into the control group (n=12) were given their prescribed 
antihypertensive medication plus placebo while those in the treatment group (n=12) were given their 
antihypertensive medication plus Ocimum basilicum L. capsules containing 128 mg of dried, powderized 
leaves once a day. Participants’ blood pressure (BP) was measured at baseline, 1 week, and 2 weeks of drug 
administration and the Mean Arterial Pressure (MAP) calculated. Results showed that systolic and diastolic 
BP in the treatment group measured from baseline, one and two weeks of drug administration are significantly 
different, whereas the control group had insignificant findings. Furthermore, the MAP in the control group 
(105.25±9.52 mm/Hg, 104.08±8.45 mm/Hg and 104.47±8.85 mmHg) were comparable while that in the 
treatment group (106.47±6.65 mm/Hg,100.89±9.99 mm/Hg, and 97.14±9.96 mm/Hg) showed significant 
lowering (p=<0.0001) over time by Repeated Measures-Anova with Bonferroni’s post-hoc test. The 
significant findings in this study support the antihypertensive action of Ocimum basilicum L. among humans 
which warrant further exploration.  
Keywords: Ocimum basilicum L.; Sweet Basil; Basil; Hypertension; Mean Arterial Pressure; Adjunct 
Therapy; Anti-Hypertensive drugs; Randomized Controlled Trial; Pilot study. 
1. INTRODUCTION 
Hypertension is one of the most pervasive chronic conditions that afflicts approximately 30% of 
adults, with a steadily increasing rate. Its complications include coronary heart disease, stroke, peripheral 
vascular disease, visual impairment and renal failure. In the presence of any of these concomitant disease or 
comorbidity, hypertension can serve as a confounding factor which can increase morbidity and mortality [1]. 
The current standard of care in the pharmacologic management of hypertension according to American Heart 
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Association (AHA) 2020 guidelines includes a Angiotensin-II converting enzyme Inhibitors (ACE-I)/ 
Angiotensin Receptor Blockers (ARB), Dihydropyridine Calcium Channel Blockers (CCB) and/or a Diuretic 
(Thiazides/Potassium Sparing) depending on the class of hypertension diagnosed, and associated 
comorbidities [2]. To date, no herbal-based remedy has yet been approved as efficacious among humans. 
However, WHO reported that about 80% of the population, especially those of developing countries still rely 
on traditional medicine for their primary health care needs [3]. Herbal based medications are also theoretically 
much cheaper and when of suitable quality, safer considering their widespread availability and use by 
indigenous populations [4].  
Studies on Ocimum basilicum L. (Sweet Basil) have shown anti-hypertensive, hepatoprotective, anti-
diabetic, hypolipidemic, analgesic, anti-inflammatory, anti-microbial, anti-oxidant, anti-ulcerogenic and 
larvicidal activities of the herb [5]. The strong clove scent of O. basilicum is derived from its compound, 
eugenol, a vanilloid molecule. The anti-hypertensive effect of Basil could be attributed to several of its 
constituents including eugenol [6-9] and linalool [10-12], postulated to have vascular vasodilatory actions. 
The anti-hypertensive properties of O. basilicum have been demonstrated on renovascular hypertensive rats in 
prior studies [13, 14]. Since basil is normally eaten, toxicity is not a problem.  This study aimed to use a 
locally available medicinal herb, O. basilicum, as an adjunct therapy to manage blood pressures of stage 1 and 
stage 2 hypertensive patients. This clinical trial is the first of its kind which determines the efficacy of basil 
among human subjects. 
2. MATERIALS AND METHODS 
 This research study was a double-blinded randomized controlled pilot clinical trial. Volunteer 
participants who fulfilled the inclusion/exclusion criteria were recruited from a village in Davao City, 
Philippines. A volunteer was considered if he/she was above the age of 18, diagnosed with stage 1 or stage 2 
hypertension as dictated by JNC7 criteria [15], and on anti-hypertensive maintenance medications. Exclusion 
criteria included patients who were medically unstable, allergic to basil, suffering from any infection or 
communicable disease, and participants on any other supplements or treatments which could affect blood 
pressure.  
The study followed a simple randomization method (fishbowl technique) to allot 24 hypertensive 
volunteer participants into two groups, the control group (n=12) and the treatment group (n=12). Participants 
in the control group were given their prescribed antihypertensive medications plus a placebo capsule while the 
treatment group received their prescribed medications plus an O. basilicum capsule daily for 2 weeks. Blood 
pressure of the participants were recorded at baseline, after 1 week, and at the end of the 2nd week. The blood 
pressure was obtained by using an aneroid sphygmomanometer. Gauge accuracy was checked visually by 
making sure that the needle rests at 0 when the unit was fully deflated. The average value of the 3 blood 
pressure recordings was noted. 
The preparation of the capsule containing basil was as follows: commercially available sweet basil 
leaves were purchased. The samples were cleaned of earthy material, rinsed with distilled water and prepared 
for cabinet drying. Services of Food Processing and Innovation Center, Philippine Women’s College, Davao 
City were utilized to assure food grade processing of the leaves, where after 6 hours of drying at 40°C, the 
dehydrated leaves were sealed and brought to Davao Medical School Foundation for encapsulation.  
Freeze drying of herbal products is used for pharmaceutical purpose as it is believed to retain the 
characteristics of the bioactive components [16]. Owing to the high cost of freeze drying, oven drying was the 
most practical option for the research team. A study on dried medicinal herb states that cabinet drying retained 
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the nutritional components of the sample efficiently. Supportive scientific facts on eugenol’s chemical 
properties assured its property retention even at 40°C [17]. 
The dosage used in this study was based on the study of Umar, 2012 [13]. A medium dose of 
200mg/kg was chosen. This effective dose in animals was converted to human effective dose using the 
formula developed by Nair, 2016 [18]. Considering the average weight of humans to be 60 kg, the 200 mg/kg 
animal effective dosage (in rats) was converted to 32mg/kg human effective dose. Human Effective Dose 
(HED) was calculated as, HED (mg/kg) = Animal dose (in mg/kg) x Animal Km/Human Km. Data obtained 
from FDA guidelines show that Rat Km is 6, whereas Human Km is 37. Hence, HED (mg/kg) = 200*6/37= 
32 mg/kg. In the prior study on hypertensive rats, a pure extract of Ocimum Basilicum leaves was used, 
whereas our study utilized powdered dried leaves instead.  
The effective human dose of 1920 mg (32 mg/kg for a 60 kg adult) of fresh Ocimum basilicum L. 
leaves were crushed and upon drying and dehydrating, yielded 128 mg of dried leaves per capsule. Placebo 
capsule on the other hand was prepared by purchasing commercially available starch, which was capsulated in 
Davao Medical School Foundation Research Center, similar to the basil capsule. The appearance of the basil 
and placebo capsules were made similar as both were red in color, non-translucent and of the same size and 
shape. 
As a double blinded study, the participants and the research team members providing the participants 
with the capsule were unaware of the contents of the capsule provided (whether basil or placebo), with the 
exception of the study team personnel handling data compilation and computation. The data collected 
included systolic and diastolic blood pressure, from which Mean Arterial Pressure (MAP) was calculated. 
Mean Arterial Pressure is calculated as the sum of 1/3*systolic BP + 2/3*diastolic BP. All data were stored on 
a secured, encrypted server and were accessible only to study team personnel. Statistical analysis was done 
using Repeated Measures Analysis of Variance (with 95% confidence interval) with Bonferroni’s post-hoc test 
which determined where the significant differences lie among the groups through time.  
3. RESULTS 
 Twenty four (24) adult hypertensive volunteers were randomly assigned to to the control (n=12), and 
the treatment (n=12) group. No attrition was reported, and results of all the participants were appropriately 
analysed. Table 1 shows the demographic and baseline characteristics of the participants in the study. 
Comparison between the control and treatment group showed no significant difference in all parameters 
measured. Thus, the two groups were comparable at the beginning of the study. 
 
Table 1. Comparison of the baseline characteristics among the participants in the control and treatment groups analyzed 
using independent t-test for continuous and Chi-square test for categorical variables. 
Variable Control group Treatment group p-value 
Age (Mean ± SD) 50.92 ± 20.44 55.92 ± 10.54 0.459 
Sex (Freq/%) 
Male 7 (29%) 3 (13%) 
0.098 
Female 5 (21%) 9 (37%) 
Baseline BP (Mean ± SD) 
Systolic 140.42 ± 19.50 139.58 ± 8.69 0.894 
Diastolic 87.67 ± 6.47 89.92 ± 7.55 0.441 
Baseline MAP (Mean ± SD) 105.30 ± 9.52 107.10 ± 6.674 0.590 
*Significant p-value at 0.05 level. 
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 Data on the blood pressure monitoring showed that the mean systolic and diastolic blood pressures of 
the participants in both the control and treatment groups had a general downward trend over time (Table 2). 
However when this trend was analyzed through Repeated Measures ANOVA, no significant difference was 
found in the control group from baseline, 1 week and 2 weeks of drug administration.  On the other hand, the 
mean systolic and diastolic blood presures of the participants in the treatment group were significantly 
different over time (Table 2). This means that the addition of basil capsule in the treatment group resulted to 
significant additional lowering of the blood pressure among the participants over time.  
 A similar trend was noted in the MAP with significant lowering over time in the treatment group and 
no significant difference in the control group (Table 2).     
 
Table 2. Comparison of the mean systolic, diastolic and MAP of the participants in the control and treatment group over 
time analysed using repeated measures ANOVA with Bonferroni post-hoc test. 
Variable Group Time Mean ± SD p-value 
Systolic 
Control 
Baseline 140.42 ± 19.50 
0.105 After 1 week 137.58 ± 16.78 
After 2 weeks 136.83 ± 17.01 
Treatment 
Baseline 139.58 ± 8.69b,c 
< 0.0001* After 1 week 133.00 ± 12.63a,c 
After 2 weeks 127.58 ± 13.73a,b 
Diastolic 
Control 
Baseline 87.67 ± 6.47 
0.457 After 1 week 87.33 ± 6.51 
After 2 weeks 86.25 ± 4.73 
Treatment 
Baseline 89.92 ± 8.69b,c 
0.001* After 1 week 84.83 ± 10.10a 
After 2 weeks 81.92 ± 9.39a 
MAP 
Control 
Baseline 105.21 ± 9.51 
0.137 After 1 week 104.05 ± 8.46 
After 2 weeks 103.08 ± 7.75 
Treatment 
Baseline 106.43 ± 6.66b,c 
< 0.0001* After 1 week 100.86 ± 10.00a 
After 2 weeks 97.10 ± 9.95a 
*Significant p-value at 0.05 level. a. Significantly different to Baseline. b. Significantly different to after 1 week. c. Significantly different 
to after 2 weeks. 
 
Bonferroni’s post-hoc test further revealed that the significant difference in the systolic pressure was 
noted between 1 and 2 weeks while that in the diastolic pressure was noted between baseline and 1 week but 
no significant lowering was noted between 1 and 2 weeks. This could mean that for the systolic pressure, 
basil’s most significant lowering effect was noted on the 2nd week of drug administration.  On the other hand, 
the effect of basil for the diastolic pressure was noted earlier after the 1st week and levelled off towards the 2nd 
week. This same observation was noted for the MAP. Overall, the results showed that the addition of basil 
capsule (128 mg/capsule) on the maintenance antihypertensive drugs prescribed to the participants caused 
further lowering of blood pressure starting at 1 week and continued on up to the 2nd week of basil 
administration. No unintended or adverse effects were noted. 
 
Ratta et al.   Sweet basil leaves as adjunct therapy for stage 1 and 2 hypertension 5 
MicroMedicine 2021; 9(1): 1-7 
4. DISCUSSION 
Ocimum basilicum L., Sweet Basil has a variety of proven and postulated benefits, of which the anti-
hypertensive effect was demonstrated in humans in this pilot study. Through the centuries, basil was 
cultivated for culinary and medicinal purposes in many countries, which created a great diversity of species 
within the Ocimum genus: the genus Ocimum comprises more than 150 species and is considered as one of the 
largest genera of the Lamiaceae family [19].  
Major constituents of the essential oil extracted from Ocimum basilicum varies by region, possibly 
varying with season, cultivation and subspecies. The aroma of each subspecies of O. basilicum is dependent 
on its major chemical constituents including monoterpenes and phenylpropanoids. In a study on 270 sweet 
basil accessions, the main components in the essential oils found were linalool (max. 71%), methyl chavicol 
(max. 92%), citral (max. 80%) and 1,8 cineole (max. 25%) as well as camphor (max. 63%), thymol (max. 
35%), (E)-methyl cinnamate (max. 77%), eugenol (max. 80%), methyleugenol (max. 79%), methyl 
isoeugenol (max. 36%) and elemicin (max. 47%) [20]. 
A European study published in 2020 revealed that the major components of Ocimum basilicum L. 
essential oil include linalool (18.0–68.0%), methyl chavicol (0.0–57.3%), geraniol (0.0–16.5%), 1,8-cineole 
(1.4–15.1%), p-allylanisole (0.2–13.8%), eugenol (0.0–12.32%), limonene (0.2–10.4%) [21]. Unfortunately, 
constituents of the essential oil of O. basilicum in the Philippines is not demonstrated in any prior studies. 
This could be a good topic for future studies. 
Among the major constituents of O. basilicum mentioned in literatures, several compounds may 
contribute to the blood pressure lowering among the participants treated with the basil capsules in this study. 
These are eugenol [6-9], linalool [10-12], geraniol [22, 23] and limonene [24, 25].  
Eugenol is theorized to stimulate TRPV channels leading to large conductance potassium channel 
(BKCa) activation and smooth muscle hyperpolarization, leading to vasodilation [7, 8]. Vasodilation can 
decrease the peripheral vascular resistance which can decrease blood pressure, since blood pressure in a 
product of cardiac output and peripheral resistance [9]. Any factor that can decreases peripheral resistance will 
also decrease blood pressure. 
Linalool is a terpene alcohol present in large quantities in O. basilicum, especially in the European 
varieties. Linalool demonstrated a dose-dependent vasodilatory effect in hypertensive rats, and elicits these 
effects by activation of guanylyl cyclase and K+ channels in vasculature of the rats, and increased levels of 
anti-inflammatory cytokine IL-10 [10-12]. 
Geraniol, present in minor quantities was found to alleviate complications of diabetes in rats, 
especially improving vascular reactivity through a calcium channel blocking effect [22, 23]. Limonene, 
present in minor quantities in O. basilicum is considered as a lipid lowering agent with antioxidant properties, 
and may also have blood pressure lowering qualities [24, 25]. Hence, these preclinical studies have 
demonstrated that many components of O. basilicum possess anti-hypertensive effect, especially eugenol and 
linalool present in relatively high quantities in varieties of Ocimum basilicum L. 
Basil can be grown easily in anyone’s backyard and the fact that it’s considered food, people can be 
assured of its safety. Oven drying at 40ºC can be done in an ordinary household oven so the usefulness of 
basil can easily be utilized by the community. The results of this study should encourage other researchers to 
do a follow up study in a bigger population. Dosage range can also be explored. Regardless of this being a 
pilot study with a small sample size, the results are nevertheless encouraging. Thus, future researches are 
warranted which can validate the results of this study in a bigger population. 
Ratta et al.   Sweet basil leaves as adjunct therapy for stage 1 and 2 hypertension 6 
MicroMedicine 2021; 9(1): 1-7 
5. CONCLUSION 
This pilot clinical trial demonstrated a significant anti-hypertensive effect of Ocimum basilicum L. 
(Sweet Basil) dried leaves at 128 mg/capsule, one capsule a day as adjunct to maintenance antihypertensive 
medication that led to further lowering of the blood pressure among Stage 1 and 2 hypertensive patients. 
Further studies are warranted. 
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